Dyne Therapeutics, Inc. (DYN)
NASDAQ:DYN
Want to see DYN full AI Analyst Report?
Top Page
Dyne Therapeutics
(NASDAQ:DYN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$16.50
▼(-19.16% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily constrained by weak financial performance (no revenue, large and rising losses, and heavy cash burn). Technicals also lean bearish with the stock below key moving averages and mildly negative momentum. Positive trial-related corporate updates support the outlook but are tempered by dilution risk from increased share authorization, while valuation remains challenged due to ongoing losses.
Positive Factors
FORCE platform
Dyne’s FORCE platform is a durable scientific differentiator: a delivery technology that can be reused across multiple neuromuscular programs, raising the long-term upside from a single successful modality. Platform utility supports pipeline breadth, partnering and licensing optionality independent of short-term trial noise.
Negative Factors
No revenue & rising losses
As a clinical-stage biotech with no product revenue and widening net losses, Dyne remains structurally dependent on external financing or partnerships. Persistent operating losses mean value realization hinges on successful trials and approvals, leaving long-term sustainability exposed to clinical and regulatory outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
FORCE platform
Dyne’s FORCE platform is a durable scientific differentiator: a delivery technology that can be reused across multiple neuromuscular programs, raising the long-term upside from a single successful modality. Platform utility supports pipeline breadth, partnering and licensing optionality independent of short-term trial noise.
Read all positive factors
Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.96B
Dividend YieldN/A
Average Volume (3M)1.46M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS Growth10.17%
CountryUS
Employees192
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.22
Shares Outstanding165,313,800
10 Day Avg. Volume1,516,869
30 Day Avg. Volume1,460,783
Financial Highlights & Ratios
PEG Ratio-1.90
Price to Book (P/B)2.58
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.30K
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$36.70Price Target Upside79.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.08
Revenue Forecast (FY)N/A
Dyne Therapeutics Business Overview & Revenue Model
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, ...
How the Company Makes Money
Dyne Therapeutics does not market approved products and therefore does not generate recurring product sales revenue; as a clinical-stage biotech, its ability to make money primarily depends on raising capital and monetizing its R&D assets. Revenue...
Dyne Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.07M | -2.05M | -2.24M | -2.46M | 0.00 | 0.00 |
| EBITDA | -441.38M | -437.97M | -315.18M | -233.48M | -169.28M | -148.94M |
| Net Income | -451.71M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
Balance Sheet | ||||||
| Total Assets | 1.08B | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Cash, Cash Equivalents and Short-Term Investments | 972.16M | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Total Debt | 19.30M | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M |
| Total Liabilities | 214.90M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Stockholders Equity | 865.05M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
Cash Flow | ||||||
| Free Cash Flow | -462.19M | -405.13M | -294.75M | -188.89M | -156.71M | -123.18M |
| Operating Cash Flow | -442.24M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Investing Cash Flow | -32.60M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Financing Cash Flow | 756.13M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
Dyne Therapeutics Technical Analysis
Positive
20.41
Price Trends
18.24
Negative
17.66
Positive
17.49
Positive
Market Momentum
-0.11
Positive
50.21
Neutral
22.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 20.41 is above the 20-day moving average (MA) of 17.77, above the 50-day MA of 18.24, and above the 200-day MA of 17.49, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 50.21 is Neutral, neither overbought nor oversold. The STOCH value of 22.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.
Dyne Therapeutics Risk Analysis
Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dyne Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $2.85B | -1,240.84 | -1.41% | ― | 95.29% | 98.21% | |
61 Neutral | $1.45B | ― | -4.83% | ― | 23.64% | -29.23% | |
54 Neutral | $1.68B | 25.64 | 4.89% | ― | -2.20% | 77.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.13B | -48.38 | -5.89% | ― | 157.97% | 86.11% | |
46 Neutral | $2.96B | -6.55 | -58.28% | ― | ― | 10.17% | |
45 Neutral | $5.46B | -6.08 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
DYN
Dyne Therapeutics
17.92
3.14
21.24%
SRPT
Sarepta Therapeutics
15.89
-23.18
-59.33%
COGT
Cogent Biosciences
31.98
24.56
331.00%
ARQT
Arcutis Biotherapeutics
22.79
8.90
64.07%
BEAM
Beam Therapeutics
30.47
12.39
68.53%
IMCR
Immunocore Holdings
28.52
-7.41
-20.62%
Dyne Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
Positive
Jun 8, 2026
On June 5, 2026, Dyne Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders elected David Lubner, Brian Posner and Jason Rhodes as Class III directors for terms expiring at the 2029 annual meeting. Investors also appr...
Business Operations and StrategyProduct-Related Announcements
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy
Positive
Jun 3, 2026
On June 3, 2026, Dyne Therapeutics announced it has fully enrolled 71 participants in the registrational expansion cohort of its global Phase 1/2 ACHIEVE trial of zeleciment basivarsen in myotonic dystrophy type 1. The trial, which selected a regi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.